Calidi Biotherapeutics Inc. Reports Q2 2025 Results and Advances in Oncology Therapies

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company focused on developing targeted therapies for metastatic diseases, announced its financial results for the second quarter of 2025. The company reported a net loss of $5.7 million, or $1.99 per share, an improvement from the net loss of $7.4 million, or $16.75 per share, in the same quarter the previous year. Research and development (R&D) expenses increased to $2.6 million from $2.2 million, while general and administrative (G&A) expenses decreased to $3.1 million from $3.6 million. Calidi ended the quarter with $5.3 million in cash and $0.1 million in restricted cash.

Among the quarter's highlights was the release of new preclinical data on CLD-401 from Calidi's proprietary RedTail platform. This data demonstrated enhanced efficacy through the systemic delivery of an IL15 superagonist and immune-evasion via engineered CD55 expression. Additionally, Calidi raised $4.6 million through a warrant inducement offering, bringing the total gross proceeds for 2025 to $15.7 million. A significant milestone was achieved with the FDA granting Fast Track Designation for CLD-201 in the treatment of soft tissue sarcoma, alongside an open Investigational New Drug (IND) application for a Phase 1 trial.

Calidi Biotherapeutics is at the forefront of immuno-oncology, pioneering the development of therapies that aim to deliver genetic medicines to distant disease sites. The company's RedTail platform utilizes an engineered enveloped oncolytic virus designed for systemic delivery, targeting metastatic sites while evading immune clearance. This technology is intended to enable virotherapy to reach tumor sites effectively, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the RedTail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs.

For more detailed information on Calidi Biotherapeutics' latest developments and financial results, visit https://ibn.fm/K3CfE. Further updates and news relating to CLDI can be found in the company's newsroom at https://ibn.fm/CLDI.